Sorrento files for bankruptcy but Scilex to operate as usual

14 February 2023

Sorrento Therapeutics (Nasdaq: SRNE), a US company focused on acquiring, developing and commercializing non-opioid pain management products, has issued a statement alongside its majority-owned subsidiary Scilex Holding Company (Nasdaq: SCLX).

The statement explains that Sorrento has begun voluntary proceedings under Chapter 11 of the US Bankruptcy Code in a court in Texas, USA.

While Scilex is majority-owned by Sorrento, it is not a debtor in Sorrento’s bankruptcy filing and will continue to operate its business as usual, the statement explains.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK